KDA Treatment Guidelines for Diabetes
- Page path
-
- Home
- Resources
- KDA Treatment Guidelines for Diabetes
- Resources
KDA Treatment Guidelines for Diabetes
- Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017
-
- 2020.03.17
- Hit 1198
- https://e-dmj.org/search.php?where=aview&id=10.4093/dmj.2017.41.5.367&code=2004DMJ&vmode=FULL (클릭 117회)
Open Access
| Diabetes Metab J. 2017 Oct;41(5):367-373. English. Published online Oct 24, 2017. https://doi.org/10.4093/dmj.2017.41.5.367 |
|
| Copyright © 2017 Korean Diabetes Association | |
| Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017 | |
Byung-Wan Lee,1,* Jin Hwa Kim,2,* Seung-Hyun Ko , 3 Kyu-Yeon Hur,4 Nan-Hee Kim,5 Sang Youl Rhee,6 Hyun Jin Kim,7 Min Kyong Moon,8 Seok-O Park,9 Kyung Mook Choi,5 and Committee of Clinical Practice Guideline of Korean Diabetes Association |
|
| 1Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. | |
| 2Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea. | |
| 3Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. | |
| 4Division of Endocrinology and Metabolism, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. | |
| 5Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. | |
| 6Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea. | |
| 7Division of Endocrinology and Metabolism, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea. | |
| 8Department of Internal Medicine, Seoul Metropolitan Government Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea. | |
| 9Department of Internal Medicine, Gwangmyeong Sungae Hospital, Gwangmyeong, Korea. | |
|
Corresponding author: Seung-Hyun Ko. Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent' Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon 16247, Korea.
*Byung-Wan Lee and Jin Hwa Kim contributed equally to this study as first authors. |
|
| Received September 08, 2017; Accepted September 25, 2017. |
|
|
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
 This article has been cited by 3 articles in   This article has been cited by 4 articles in KoMCI. This article has been cited by Google Scholar. This article has been cited by 2 articles in Scopus. This article has been cited by 2 articles in Web of Science. |
|
|
Abstract
|
|
The Korean Diabetes Association (KDA) has regularly updated its Clinical Practice Guidelines. In 2017, the KDA published a position statement on the use of antihyperglycemic agents for patients with type 2 diabetes mellitus (T2DM). Growing evidence from new multinational clinical trials using novel and traditional insulin analogues has also been accumulated. Following global trends, many results of clinical trials, especially concerning the clinical efficacy and safety of insulin therapy, have been published about Korean patients with T2DM. After a systematic search of recent evidence, the KDA updated and modified its clinical practice recommendations regarding the initiation, choice, and intensification of insulin and created an insulin treatment algorithm for the first time to guide physicians caring for adult Korean patients with T2DM. |
|
|
Keywords:
Clinical practice guideline; Diabetes mellitus, type 2; Hypoglycemic agents; Insulin; Korea
|
|